Welcome to our dedicated page for Citius Pharmaceuticals news (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals stock.
Citius Pharmaceuticals Inc. (CTXR) delivers innovative therapies for critical care needs through its pipeline of novel oncology treatments and anti-infective solutions. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company's progress.
Access verified information about CTXR's FDA interactions, trial results for therapies like LYMPHIR™ and Mino-Lok®, and partnership announcements. Our curated collection ensures you stay informed about material events without promotional bias, supporting data-driven decision-making in this specialized biopharmaceutical sector.
Key updates include progress reports on late-stage clinical programs, manufacturing expansions, and peer-reviewed research publications. All content undergoes strict verification to maintain compliance with financial disclosure standards while preserving accessibility for both medical and investment audiences.
Bookmark this page for streamlined tracking of CTXR's advancements in targeted immunotherapies and critical care innovations. Combine regular monitoring with professional financial advice to maintain perspective on the company's evolving market position.
Citius Pharmaceuticals (CTXR) reported its fiscal Q2 2024 financial results and provided a business update. Key highlights include:
- The FDA accepted LYMPHIR's BLA with a PDUFA target date of Aug 13, 2024.
- Topline results for Mino-Lok’s Phase 3 trial expected in Q2 2024.
- Continued engagement with FDA for Halo-Lido’s development.
- Merger with TenX Keane Acquisition progressing, awaiting SEC and TENK shareholder approval.
- Completed a $15M direct offering in April 2024, extending cash runway to Dec 2024.
Financial highlights:
- $12.6M in cash as of Mar 31, 2024.
- R&D expenses decreased to $3.6M from $4.7M YoY; G&A expenses slightly decreased to $4.3M from $4.8M YoY.
- Net loss improved to $8.5M, $0.05 per share, from $10.5M, $0.07 per share YoY.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) will participate in the upcoming EF Hutton and H.C. Wainwright investor conferences. CEO Leonard Mazur will host one-on-one investor meetings at the EF Hutton Annual Global Conference on May 15, 2024, and present at the H.C. Wainwright BioConnect Investor Conference on May 20, 2024.
Citius Pharmaceuticals Inc. (Nasdaq: CTXR) closed a registered direct offering, raising $15 million through the sale of 21,428,574 shares and warrants. The offering was facilitated by H.C. Wainwright & Co. The company plans to utilize the funds for general corporate purposes, including product development and working capital.
FAQ
What is the current stock price of Citius Pharmaceuticals (CTXR)?
What is the market cap of Citius Pharmaceuticals (CTXR)?
